Research Topics
Species | D E CohnSummaryAffiliation: The Ohio State University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancerDavid E Cohn
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The Ohio State University College of Medicine and Comprehensive Cancer Center, 320 West 10th Avenue, M 210 Starling Loving Hall, Columbus, OH 43210, USA
Gynecol Oncol 102:134-9. 2006..To determine the ability of patients to be treated with biweekly bevacizumab and weekly taxane chemotherapy in women with advanced, refractory ovarian cancer...- Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancerDavid E Cohn
Division of Gynecologic Oncology, Washington University School of Medicine, St Louis, Missouri, USA
Gynecol Oncol 85:179-84. 2002..We set out to determine the ability of positron emission tomography with fluorodeoxyglucose to detect groin lymph node metastases from vulvar cancer... - HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patientsCarl Morrison
Department of Pathology, Division of Gynecologic Oncology Center for Biostatistics, The Arthur James Cancer Hospital, and the Richard Solove Research Institute, The Ohio State University Medical School Columbus, OH 43210, USA
J Clin Oncol 24:2376-85. 2006..To evaluate HER-2 expression and amplification in a large cohort of endometrial cancer with complete surgical staging and outcome data... - Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patientsHeather Hampel
Human Cancer Genetics Program, The Ohio State University Comprehensive Cancer Center, 420 West 12th Avenue, Columbus, OH 43210, USA
Cancer Res 66:7810-7. 2006..Studying all endometrial cancer patients for Lynch syndrome using a combination of MSI and immunohistochemistry for molecular prescreening followed by gene sequencing and deletion analysis is feasible and may be desirable... - Correlation between patient weight and defects in DNA mismatch repair: is this the link between an increased risk of previous cancer in thinner women with endometrial cancer?D E Cohn
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The Ohio State University College of Medicine, Columbus, Ohio, USA
Int J Gynecol Cancer 18:136-40. 2008.... - Cost-effectiveness analysis of strategies for the surgical management of grade 1 endometrial adenocarcinomaDavid E Cohn
Division of Gynecologic Oncology, Ohio State University College of Medicine, Columbus, Ohio, USA
Obstet Gynecol 109:1388-95. 2007..To estimate the costs and outcomes of various strategies used for the management of grade 1 endometrial cancer... - Residents' perspectives on surgical training and the resident-fellow relationship: comparing residency programs with and without gynecological oncology fellowshipsD E Cohn
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, Ohio, USA
Int J Gynecol Cancer 18:199-204. 2008..While fellows are often thought of as a detracting factor to residency training, they do not appear to affect the perception of the quality of resident surgical training... 
Comprehensive miRNA profiling of surgically staged endometrial cancerDavid E Cohn
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, OH, USA
Am J Obstet Gynecol 202:656.e1-8. 2010..We sought to determine a microRNA (miRNA) profile of surgically staged endometrial cancers...- At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysisDavid E Cohn
The Ohio State University College of Medicine, Columbus, OH, USA
J Clin Oncol 29:1247-51. 2011..To determine whether the addition of bevacizumab to paclitaxel and carboplatin for the primary treatment of advanced ovarian cancer can be cost effective... - Non-Hodgkin's lymphoma mimicking gynecological malignancies of the vagina and cervix: a report of four casesD E Cohn
Departments of Obstetrics and Gynecology, Division of Gynecologic Oncology, The Ohio State University College of Medicine, 320 West 10th Avenue, Columbus, OH 43210, USA
Int J Gynecol Cancer 17:274-9. 2007..A correct diagnosis leads to the appropriate therapy, and radical gynecological surgery can be avoided for primary cervical and vaginal lymphoma... - Improved survival with an intact DNA mismatch repair system in endometrial cancerDavid E Cohn
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, Ohio 43210, USA
Obstet Gynecol 108:1208-15. 2006..To correlate survival and surgical-pathologic factors with DNA mismatch repair status in patients with endometrial cancer... - Novel perioperative imaging with 18F-FDG PET/CT and intraoperative 18F-FDG detection using a handheld gamma probe in recurrent ovarian cancerDavid E Cohn
The Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, OH 43210 1228, USA
Gynecol Oncol 110:152-7. 2008..We describe an innovative approach for intraoperative tumor localization and verification of tumor resection utilizing (18)F-FDG for perioperative PET/CT imaging and intraoperative gamma probe detection in ovarian cancer... - Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancerJ D Hurt
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, M 210 Starling Loving Hall, 320 West 10th Avenue, Columbus, OH 43210, USA
Gynecol Oncol 115:396-400. 2009..To determine efficacy, toxicity, and survival in patients with recurrent epithelial ovarian cancer (EOC) receiving combination of weekly paclitaxel and biweekly bevacizumab (PB)... - Atypical clustering of gynecologic malignancies: A family study including molecular analysis of candidate genesD E Cohn
Division of Gynecologic Oncology, Washington University School of Medicine, St Louis, Missouri 63110, USA
Gynecol Oncol 77:18-25. 2000..We set out to determine whether hereditary nonpolyposis colorectal cancer (HNPCC) was responsible for cancer susceptibility in a family with gynecologic malignancies in three consecutive generations... - Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?D L Richardson
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, M 210 Starling Loving Hall, 320 West 10th Avenue, Columbus, OH 43210, USA
Gynecol Oncol 118:47-51. 2010..We sought to identify factors associated with bowel perforation and fistula formation in recurrent EOC patients treated with bevacizumab... - Radical hysterectomy for cervical cancer in obese womenD E Cohn
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, St Louis, Missouri, USA
Obstet Gynecol 96:727-31. 2000..To estimate the morbidity, adequacy of surgery, and survival of obese women undergoing radical hysterectomy and pelvic lymphadenectomy... - Multicenter analysis of recurrence and survival in stage IIIA endometrial cancerLaura J Havrilesky
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Cente, Durham, North Carolina 27710, USA
Gynecol Oncol 114:279-83. 2009..To determine factors related to recurrence and survival in women with stage IIIA endometrial cancer; to examine outcomes of women with IIIA1 disease... - Absence of PTEN repeat tract mutation in endometrial cancers with microsatellite instabilityD E Cohn
Department of Obstetrics and Gynecology, Washington University School of Medicine, St Louis, Missouri 63110, USA
Gynecol Oncol 79:101-6. 2000..We set out to investigate the relationship between MSI and PTEN mutation in a large series of primary endometrial carcinomas... - Surgical staging for patients presenting with grade 1 endometrial carcinomaInbar Ben-Shachar
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio State University College of Medicine and Public Health, USA
Obstet Gynecol 105:487-93. 2005..Omitting lymphadenectomy in patients presenting with grade 1 endometrial cancer may lead to inappropriate postoperative management... - Is selective lymphadenectomy more cost-effective than routine lymphadenectomy in patients with endometrial cancer?A E Clements
Divisions of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, OH, USA
Gynecol Oncol 128:166-70. 2013..The objective of this study is to determine the cost-effectiveness of two strategies in women undergoing surgery for newly diagnosed endometrial cancer... - Minimally invasive comprehensive surgical staging for endometrial cancer: Robotics or laparoscopy?Leigh G Seamon
The Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, OH 43210 1228, USA
Gynecol Oncol 113:36-41. 2009..To compare outcomes between robotic versus laparoscopic hysterectomy and lymphadenectomy in patients with endometrial cancer... - Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer?David E Cohn
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Arthur G James Cancer Hospital and Solove Research Institute, The Ohio State University College of Medicine, Columbus, Ohio 43210, USA
Gynecol Oncol 87:243-6. 2002..As such, the presence of LVSI may indicate the need for lymphadenectomy or adjuvant therapy for potential regional lymph node metastases in patients with unstaged endometrial cancer... - CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapyDebra L Richardson
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, USA
Gynecol Oncol 111:233-6. 2008..The secondary objectives are to determine if the time to normal CA125 levels and time to nadir of CA125 differ between the groups... - Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancerDebra L Richardson
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The Ohio State University College of Medicine, Columbus, OH, USA
Gynecol Oncol 111:461-6. 2008..To describe the response rate (RR), progression-free survival (PFS), and toxicity profile of combination gemcitabine, platinum, and bevacizumab (GPB) for the treatment of recurrent epithelial ovarian cancer (EOC)... - Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancerFloor J Backes
The Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, OH 43210 1228, USA
Gynecol Oncol 114:486-90. 2009..We report our experience with the prospective evaluation of MMR protein expression in endometrial cancer... - Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancerLeigh G Seamon
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine and Arthur G James Cancer Hospital and Solove Research Institute, Columbus, OH 43210 1228, USA
Int J Gynecol Cancer 19:1195-8. 2009..We describe the toxicity profile of an outpatient regimen of an intravenous (IV) and IP taxane-platinum chemotherapy... - Outcomes following percutaneous upper gastrointestinal decompressive tube placement for malignant bowel obstruction in ovarian cancerK S Rath
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The Wexner Medical Center at Ohio State University, Columbus, OH 43210, USA
Gynecol Oncol 129:103-6. 2013..The objective of this study was to evaluate peri-operative and survival outcomes of ovarian cancer patients undergoing percutaneous upper gastrointestinal decompression for malignant bowel obstruction (MBO)... - Factors predicting subcutaneous implanted central venous port function: the relationship between catheter tip location and port failure in patients with gynecologic malignanciesD E Cohn
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, 4911 Barnes Hospital Plaza, St. Louis, Missouri 63110, USA
Gynecol Oncol 83:533-6. 2001..Confirmation of the location of the catheter tip is imperative for the long-term function of a subcutaneous implanted central venous port... - Vaginal evisceration during intraperitoneal chemotherapy for advanced ovarian cancerAmy M Burkett
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, 320 West 10th Avenue, M 210 Starling Loving Hall, The Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, OH 43210, USA
Gynecol Oncol 104:491-3. 2007..We present a case of vaginal evisceration during intraperitoneal chemotherapy for advanced ovarian cancer... - Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapyJeanne M Schilder
Department of Ob Gyn, Division of Gynecologic Oncology, Indiana University Medical Center, 535 Barnhill Drive, Rm 436, Indianapolis, IN 46202 6294, USA
Gynecol Oncol 87:1-7. 2002..The purpose of this study was to determine the recurrence rate, survival, and pregnancy outcome in patients with Stage IA and Stage IC invasive epithelial ovarian cancer treated with unilateral adnexectomy... 
Identification of candidate epigenetic biomarkers for ovarian cancer detectionYi Wen Huang
Molecular Biology and Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
Oncol Rep 22:853-61. 2009..Molecular therapies, by reversing the aberrant epigenomes using inhibitory agents or by abrogating the upstream signaling pathways that convey the epigenomic perturbations, may be developed into promising treatment regimens...- Morbid obesity and endometrial cancer: surgical, clinical, and pathologic outcomes in surgically managed patientsJames C Pavelka
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine and Public Health, 320 West 10th Avenue, Columbus, OH 43210, USA
Gynecol Oncol 95:588-92. 2004..Staging remains important in obese women, as the risk of extrauterine disease, including lymph node metastasis, is similar to that in women with ideal body weight... - Sequential chemotherapy and irradiation in advanced stage endometrial cancer: A Gynecologic Oncology Group phase I trial of doxorubicin-cisplatin followed by whole abdomen irradiationJeffrey M Fowler
The Ohio State University, Gynecologic Oncology, M210 Starling Loving Hall, 320 West Tenth Avenue, Columbus, OH 43210 1228, USA
Gynecol Oncol 112:553-7. 2009..The objective of this study was to evaluate the feasibility and toxicity of delivering sequential doxorubicin-cisplatin (AC) followed by whole abdomen irradiation (WAI)... - The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platformKimberly E Resnick
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The Ohio State University College of Medicine, Columbus, Ohio 43210, USA
Gynecol Oncol 112:55-9. 2009..To determine the utility of serum miRNAs as biomarkers for epithelial ovarian cancer... - Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experienceW K Huh
Division of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, Alabama 35249, USA
Int J Gynecol Cancer 17:886-9. 2007.... - Comprehensive surgical staging for endometrial cancer in obese patients: comparing robotics and laparotomyLeigh G Seamon
Divisions of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University, Columbus, Ohio, USA
Obstet Gynecol 114:16-21. 2009..To compare adequacy and outcomes of surgical staging for endometrial cancer in obese women by robotics or laparotomy... - Clinical and pathologic correlates in surgical stage II endometrial carcinomaDavid E Cohn
Division of Gynecologic Oncology, Ohio State University College of Medicine, Columbus, Ohio, USA
Obstet Gynecol 109:1062-7. 2007..To identify the surgical, pathologic, and therapeutic factors that influence outcome in patients with surgical stage II endometrial adenocarcinoma... - A detailed analysis of the learning curve: robotic hysterectomy and pelvic-aortic lymphadenectomy for endometrial cancerLeigh G Seamon
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University, Columbus, Ohio 43210 1228, USA
Gynecol Oncol 114:162-7. 2009..To define the learning curve for robotic hysterectomy and pelvic-aortic lymphadenectomy for endometrial carcinoma... - Are prediction models for Lynch syndrome valid for probands with endometrial cancer?Floor J Backes
The Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, OH 43210 1228, USA
Fam Cancer 8:483-7. 2009..Further studies are needed to develop models that include questions specific to patients with EMC with a greater age range, as well as placing increased emphasis on prediction of LS in probands with MSH6 mutations... - Gestational trophoblastic diseases: new standards for therapyD E Cohn
Department of Obstetrics and Gynecology, Washington University School of Medicine, St Louis, Missouri 63110, USA
Curr Opin Oncol 12:492-6. 2000..This review highlights these recent advancements in the epidemiology, genetics, diagnosis, and treatment of gestational trophoblastic disease... - Meigs' syndrome with an elevated CA 125 from benign Brenner tumorsB M Buttin
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, St. Louis, Missouri 63110, USA
Obstet Gynecol 98:980-2. 2001..CONCLUSION: Cytologic or histologic confirmation of malignancy is imperative in patients with a pelvic mass, ascites, hydrothorax, and elevated CA 125 before initiating chemotherapy... - Mismatch repair status and outcomes after adjuvant therapy in patients with surgically staged endometrial cancerKimberly E Resnick
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, OH 43210, USA
Gynecol Oncol 117:234-8. 2010..To determine whether DNA mismatch repair (MMR) modifies the response to chemotherapy or radiotherapy in patients with endometrial cancer... - The prognostic significance of the triple negative phenotype in endometrial cancerRajul Kothari
Division of Gynecologic Oncology, University of Minnesota Medical Center, 420 Delaware Street SE, Minneapolis, MN 55455, USA
Gynecol Oncol 118:172-5. 2010..To determine if the triple negative phenotype (TNP) has prognostic significance in endometrial cancer with respect to various surgicopathologic outcomes and survival... - Is there a prognostic difference between depth of myometrial invasion and the tumor-free distance from the uterine serosa in endometrial cancer?Jaina Lindauer
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine and Public Health, Columbus, OH 43210, USA
Gynecol Oncol 91:547-51. 2003..The objective was to determine whether tumor-free distance from the uterine serosa is more predictive of patient outcome than depth of endometrial cancer invasion into the myometrium... - Prospective evaluation of prognostic significance of the tumor-free distance from uterine serosa in surgically staged endometrial adenocarcinomaKatherine V Schwab
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Ohio State University College of Medicine, Columbus, Ohio 43210, USA
Gynecol Oncol 112:146-9. 2009.... - Panniculectomy concurrent with anterior pelvic exenteration for recurrent cervical cancerDebra L Richardson
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, OH, USA
Gynecol Oncol 108:449-51. 2008..Panniculectomy concurrent with gynecologic cancer surgery is safe and facilitates pelvic exposure in the morbidly obese patient... - Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysisJeffrey M Fowler
Division of Gynecologic Oncology, The Ohio State University Medical School, Columbus, OH 43210, USA
Am J Obstet Gynecol 192:1262-71; discussion 1271-3. 2005.... - Advanced endometrial cancer with serous metastasis in a 17-year-oldDavid E Cohn
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The Ohio State University College of Medicine, 320 West 10th Avenue, M 210 Starling Loving Hall, Columbus, OH 43210, USA
Gynecol Oncol 101:356-9. 2006..We present a case of stage IIIC endometrial cancer with serous histology in a 17-year-old... - Robotic pelvic and aortic lymphadenectomy for endometrial cancer: the console surgeon's perspectives on surgical technique and directing the assistantLeigh G Seamon
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, Ohio 43210 1228, USA
J Minim Invasive Gynecol 17:180-5. 2010..Our purpose is to describe and demonstrate basic console dissection techniques in robotic hysterectomy, aortic and pelvic lymphadenectomy for endometrial carcinoma, and efficient methods to direct the assistant... - Genotypic and phenotypic progression in endometrial tumorigenesis: determining when defects in DNA mismatch repair and KRAS2 occurD E Cohn
Department of Obstetrics and Gynecology, Washington University School of Medicine, St Louis, Missouri, USA
Genes Chromosomes Cancer 32:295-301. 2001..These discordant genotypes suggest genetic heterogeneity in endometrial hyperplasia and concomitant cancer... - Lynch syndrome screening strategies among newly diagnosed endometrial cancer patientsKimberly Resnick
Division of Gynecologic Oncology, Department of Internal Medicine, Ohio State University College of Medicine, Columbus, OH 43210, USA
Obstet Gynecol 114:530-6. 2009..To estimate the cost-effectiveness of screening strategies for Lynch syndrome among newly diagnosed endometrial cancer patients... - Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group studyRobert A Burger
Department of Obstetrics and Gynecology, University of California-Irvine Medical Center, Orange, CA, USA
Cancer 101:106-15. 2004.... - Robotic hysterectomy and pelvic-aortic lymphadenectomy for endometrial cancerLeigh G Seamon
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, and the Center for Biostatistics, The Ohio State University College of Medicine, Columbus, Ohio 43210 1228, USA
Obstet Gynecol 112:1207-13. 2008..To report the learning curve and outcomes after our first 105 patients underwent robotic hysterectomy and pelvic-aortic lymphadenectomy for the comprehensive staging of endometrial cancer... - CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sitesLindsey B De Lott
Department of Pathology, The Ohio State University Medical Center, Columbus, OH, USA
Arch Pathol Lab Med 129:1100-5. 2005..However, CDX2 is not a sensitive marker for poorly differentiated colorectal carcinoma... - Invasive cervical adenocarcinoma immediately following a cone biopsy for adenocarcinoma in situ with negative marginsDavid E Cohn
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The Ohio State University College of Medicine and Public Health, 320 West 10th Avenue, M 210 Starling Loving Hall, Columbus, OH 43210, USA
Gynecol Oncol 98:158-60. 2005..This case challenges the concept of conservative management of cervical adenocarcinoma in situ... - A multi-institutional review of outcomes of endometrial stromal sarcomaCharles A Leath
Department of Obstetrics, Division of Gynecologic Oncology, The University of Alabama at Birmingham, Birmingham, AL, USA
Gynecol Oncol 105:630-4. 2007..To compare the clinical behavior and outcomes of low- and high-grade endometrial stromal sarcomas (LGESS and HGESS), respectively... - The mucin expression profile of endometrial carcinoma and correlation with clinical-pathologic parametersCarl Morrison
Department of Pathology, Center for Biostatistics, The Ohio State University, Columbus, OH, USA
Appl Immunohistochem Mol Morphol 15:426-31. 2007..0% vs. 39/52, 75.0%, P=0.01). No significant differences in any of the mucins were noted among the other end points evaluated. Mucin expression did not correlate with tumor grade, stage, or patient outcome... - Liquid-based cytology for the postirradiation surveillance of women with gynecologic malignanciesJason D Wright
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO 63110, USA
Gynecol Oncol 91:134-8. 2003..CONCLUSIONS: ThinPrep for the surveillance of women with gynecologic malignancies treated with radiotherapy is associated with a high rate of satisfactory samples and a low rate of equivocal and ASCUS cytology... - Gynecologic malignancies in adolescentsMarshall Stepanian
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine and Public Health, Columbus, OH 43210, USA
Adolesc Med Clin 15:549-68. 2004..This article focuses on the most common gynecologic cancers in pediatric and adolescent girls, with a special emphasis on treatment that maintain fertility and positive body image... - Immunization with synthetic VEGF peptides in ovarian cancerBing Wang
College of Biological Sciences, Department of Microbiology and Medicinal Biochemistry, The Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, OH 43210, USA
Gynecol Oncol 119:564-70. 2010..To assess the role of active immunotherapy targeting VEGF with a peptide vaccine as a potential treatment for ovarian cancer... - The role of MRI in the conservative management of endometrial cancerInbar Ben-Shachar
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine and Public Health, Columbus, OH 43210, USA
Gynecol Oncol 93:233-7. 2004..CONCLUSIONS: The accuracy of MRI in detecting myoinvasion is limited, and as such results should be interpreted with caution when this information is used in counseling a young patient regarding surgical staging for endometrial cancer... - Metastatic squamous cell carcinoma of the vulva to the lung confirmed with allelotypingShelly M Seward
Division of Gynecologic Oncology, Pathology, The Ohio State University College of Medicine, Columbus, OH, USA
Int J Gynecol Pathol 28:497-501. 2009..Allelotyping for loss of heterozygosity is an effective tool to establish metastasis versus synchronous primary tumors in the presence of multiple lesions, helping to direct appropriate clinical management... - Robotic trocar site small bowel evisceration after gynecologic cancer surgeryLeigh G Seamon
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, OH, USA
Obstet Gynecol 112:462-4. 2008..Trocar site hernia is a known, rare complication after laparoscopic surgery. We describe a case of bowel herniation, evisceration, and bowel obstruction through an 8-mm robotic port site... - Local correction of extreme stomal prolapse following transverse loop colostomyLeigh G Seamon
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The Ohio State University College of Medicine, Columbus, OH, USA
Gynecol Oncol 111:549-51. 2008..Although rarely required, surgical correction is associated with potential morbidity. We describe a novel surgical approach to repair stomal herniation that aims to decrease perioperative morbidity... - Current and emerging trends in Lynch syndrome identification in women with endometrial cancerKimberly E Resnick
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, OH 43210, USA
Gynecol Oncol 114:128-34. 2009..Lynch syndrome is a heritable, cancer susceptibility syndrome. This study aims to review current and emerging trends in the identification of Lynch syndrome in the endometrial cancer patient population... - Pre-emptive analgesia in gynecologic surgical procedures: preoperative wound infiltration with ropivacaine in patients who undergo laparotomy through a midline vertical incisionGlenn M Updike
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ohio State University, Columbus, USA
Am J Obstet Gynecol 188:901-5. 2003..We tested the hypothesis that local anesthetic that is injected before a vertical midline abdominal incision would decrease the use of postoperative opioids... - A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterusAaron H Wolfson
Sylvester Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA
Gynecol Oncol 107:177-85. 2007..This study was designed to compare patient outcome following treatment with adjuvant whole abdominal irradiation (WAI) versus (vs.) chemotherapy for patients with this rare group of female pelvic malignancies... - Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation statusMichael S Gordon
Arizona Cancer Center, Tuscon and Scottsdale, AZ, USA
J Clin Oncol 24:4324-32. 2006..CONCLUSION: Pertuzumab is well tolerated with a RR of 4.3% in heavily-pretreated OC patients. Further studies on pHER2 as a diagnostic are warranted... - Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapyWarner K Huh
University of Alabama at Birmingham, Birmingham, AL 35249, USA
Gynecol Oncol 91:470-5. 2003..Our aim was to determine the outcomes of Stage I uterine papillary serous carcinoma (UPSC) patients with and without adjuvant therapy after comprehensive surgical staging... - A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?Teresa L Rutledge
University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
Gynecol Oncol 95:70-6. 2004..To compare stages IB1 and IB2 cervical cancers treated with radical hysterectomy (RH) and to define predictors of nodal status and recurrence... - Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply?Scott A Kamelle
Oklahoma Health Sciences Center, USA
Gynecol Oncol 94:249-55. 2004..To evaluate how the independent predictors of recurrence for stage IB2 cervical cancers treated with up-front radical hysterectomy apply to established risk models... - Randomized trial results of quality of life comparing whole abdominal irradiation and combination chemotherapy in advanced endometrial carcinoma: A gynecologic oncology group studyDeborah Watkins Bruner
Department of Population Science and Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Qual Life Res 16:89-100. 2007..To prospectively compare quality of life (QOL) outcomes in patients with advanced endometrial cancer treated with whole abdominal irradiation (WAI) or doxorubicin-cisplatin (AP) chemotherapy... - Comment on: Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer PatientsHeather Hampel
Cancer Res 67:9603. 2007 - Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology GroupRussell J Schilder
Department of Medical Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
Gynecol Oncol 96:103-7. 2005..A multicenter study was conducted to evaluate the activity and toxicity of gemcitabine in patients with previously treated non-squamous cell carcinoma of the uterine cervix... - Profiling microdissected epithelium and stroma to model genomic signatures for cervical carcinogenesis accommodating for covariatesDavid Gius
Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
Cancer Res 67:7113-23. 2007....